What this is
- How it works
- How it works isn't classified yet
- Tested for
- Advanced Solid Tumors, Recurrent or Progressive Glioblastoma, Relapse or Refractory Myeloid Malignancies
- Main trialPhase 1
- “This is a Phase 1, open-label, dose-escalation study of CBX-663 in participants with R/R AML, MDS or CMML (Cohort A), advanced solid tumors (Cohort B), or recurrent or progressive GBM (Cohort C) (collectively called 'indication cohorts'). Participants aged ≥18 years are planned to be enrolled. CBX-663 will initially be investigated on a fixed dosing schedule. CBX-663 will be administered intravenously (IV) on Cycle 1 Day 1 (C1D1) and then once weekly (QW) in 21-day cycles. Participants will continue treatment with CBX-663 until unacceptable toxicity, progressive disease, withdrawal of…”In the company’s words, NCT07779798 on ClinicalTrials.gov
Other drugs for Advanced Solid Tumors
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- AlectinibRoche · Phase 3
- AtezolizumabRoche · Phase 3
- AU-011Aura Biosciences · Phase 3
- BevacizumabRoche · Phase 3
- CadonilimabAkeso · Phase 3
Coming up1
- Jan 2028Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | Jan 2028 | A Phase 1, Open-Label, Dose-Escalation Study to Evaluate Safety, Tolerability, and Clinical Activity of CBX-663 in Participants With Relapsed or Refractory Myeloid Malignancies, Advanced Solid Tumors, or Recurrent or Progressive Glioblastoma. |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026